(Q27025299)

3

object named as

Michael Cohen-Wolkowiez

1 reference

Julie Autmizguine

1

1 reference

Jeffrey T. Guptill

2

1 reference

Daniel K. Benjamin

4

1 reference

Edmund V. Capparelli

5

1 reference

language of work or name

1 reference

June 2014

1 reference

1 reference

74

1 reference

issue

8

1 reference

page(s)

891-909

1 reference

Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Population pharmacokinetics of amphotericin B in children with malignant diseases

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vitro activities of four novel triazoles against Scedosporium spp

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Voriconazole-induced phototoxicity in children

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Antifungal therapy and outcomes in infants with invasive Candida infections

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Phase II dose escalation study of caspofungin for invasive Aspergillosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Fluconazole loading dose pharmacokinetics and safety in infants

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Human tissue distribution of voriconazole.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Neonatal candidiasis: epidemiology, risk factors, and clinical judgment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Population pharmacokinetics of micafungin in neonates and young infants

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Voriconazole pharmacokinetics and pharmacodynamics in children

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Safety and pharmacokinetics of repeat-dose micafungin in young infants

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetics of an elevated dosage of micafungin in premature neonates

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetics and safety of caspofungin in older infants and toddlers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Antifungal therapeutic drug monitoring: established and emerging indications

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Population pharmacokinetics of fluconazole in young infants

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Association of fluconazole pharmacodynamics with mortality in patients with candidemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetics and tissue distribution of anidulafungin in rats

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vitro and in vivo antifungal activities of T-2307, a novel arylamidine

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Posaconazole plasma concentrations in juvenile patients with invasive fungal infection

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Population pharmacokinetics of amphotericin B lipid complex in neonates

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Experience with caspofungin in the treatment of persistent fungemia in neonates

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Candidal meningitis in neonates: a 10-year review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Evaluation of voriconazole pharmacodynamics using time-kill methodology

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Agents for treatment of invasive fungal infections

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Safety and tolerability of fluconazole in children

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Organism-dependent fungicidal activities of azoles

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pretreatment regimens for adverse events related to infusion of amphotericin B.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetics of itraconazole following oral administration to normal volunteers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetics of amphotericin B in children

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Trichosporon beigelii, an emerging pathogen resistant to amphotericin B

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetics and tissue penetration of fluconazole in humans

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Amphotericin B: current understanding of mechanisms of action

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Amphotericin B Pharmacokinetics in Humans

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in h

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

The epidemiology of candidemia in two United States cities: results of a population-based active surveillance

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Amphotericin B lipid complex in pediatric patients with invasive fungal infections

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Correlation between in vitro and in vivo activity of antifungal agents against Candida species

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetic Studies on the Oral Antimycotic Agent 5-Fluorocytosine in Individuals with Normal and Impaired Kidney Function

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Mode of Action of 5-Fluorocytosine and Mechanisms of Resistance

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months

31 May 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Effects of fluid and electrolyte management on amphotericin B-induced nephrotoxicity among extremely low birth weight infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Nephrotoxicity associated with amphotericin B deoxycholate in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

A multicenter, randomized trial of prophylactic fluconazole in preterm neonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Toxicodynamics of itraconazole: implications for therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Retrospective study of the safety of caspofungin in immunocompromised pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0227-3

Safety of micafungin in pediatric clinical trials

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Caspofungin therapy of neonates with invasive candidiasis

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4073603

In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods

28 November 2018

1 reference

12 December 2020

Systemic Candida infections in infants in intensive care nurseries: high incidence of central nervous system involvement

1 reference

12 December 2020

Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients

1 reference

12 December 2020

Distribution and activity of amphotericin B in humans

1 reference

12 December 2020

The postantifungal effect of 5-fluorocytosine on Candida albicans

1 reference

12 December 2020

The efficacy of two different lipid-based amphotericin B in neonatal Candida septicemia

1 reference

12 December 2020

Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections

1 reference

12 December 2020

Pharmacokinetics and adverse effects of amphotericin B in infants and children

1 reference

12 December 2020

Pharmacokinetics of fluconazole in pediatric patients

1 reference

12 December 2020

Liposomal amphotericin B treatment for neonatal fungal infections

1 reference

12 December 2020

Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates

1 reference

12 December 2020

Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans

1 reference

12 December 2020

Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity

1 reference

12 December 2020

Pharmacokinetics of amphotericin B in infants and children

1 reference

12 December 2020

Caspofungin in the treatment of symptomatic candiduria

1 reference

12 December 2020

Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species

1 reference

12 December 2020

Oral administration of solubilized amphotericin B

1 reference

12 December 2020

10.1007/S40265-014-0227-3

Identifiers

DOI

0 references

Dimensions Publication ID

1003765026

0 references

Fatcat ID

release_bukgxrsqsnat5nzgdm6d3bnhma

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bukgxrsqsnat5nzgdm6d3bnhma

24 November 2022

mapped directly with Wikidata item

1 reference

PubMed publication ID

24872147

1 reference